poisar

Stocks · News reference

Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaBenzinga Newsdesk

    Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline

    Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last

  2. Globenewswire IncNa

    Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

    Eupraxia Pharmaceuticals held its Annual General Meeting on June 18, 2026, where all seven board nominees were elected with strong shareholder support. The company also re-appointed KPMG LLP as auditor. Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release products using its proprietary Diffusphere™ technology, with current programs in pain management and inflammatory gastrointestinal disease.